Introduction
============

Heart failure (HF) is a complex syndrome, characterized by symptoms associated with inadequate perfusion of organs and tissues during exercise, and represents the common pathway for the majority of primary cardiovascular diseases ([@b1-etm-08-01-0105]). Progressive aging of the population, together with the significant reduction in the rate of mortalities due to cardiovascular diseases, have been accompanied by a marked increase in the prevalence of HF, and HF is now considered a major public health problem ([@b2-etm-08-01-0105]).

Patients with myocardial infarction (MI) that has progressed to a late stage develop chronic HF. Chronic HF with renal insufficiency, which is known as cardiorenal syndrome (CRS), has gradually become a focus of drug discovery efforts ([@b3-etm-08-01-0105]). Congestive HF is a progressive disorder that leads to intense intrarenal vasoconstriction, elevated renal vascular resistance, reduced renal blood flow ([@b4-etm-08-01-0105]), progressive kidney damage and renal insufficiency in the later stages ([@b5-etm-08-01-0105]). The incidence of chronic cardiovascular disease is increasing and, due to the surgical treatment of numerous patients in the acute phase of the disease, the number of patients with progression of the disease to end-stage has also increased markedly; such patients often present with renal insufficiency and CRS manifestations ([@b6-etm-08-01-0105]). The pathogenesis of CRS is complex and studies have identified that excessive activation of the renin-angiotensin system (RAS) is an important risk factor ([@b7-etm-08-01-0105]). The RAS produces angiotensin II (Ang II) and participates in damaging renal hemodynamic and non-hemodynamic effects. The non-hemodynamic effects of the RAS, including the promotion of oxidative stress, are mainly generated by Ang II local to an organ ([@b8-etm-08-01-0105]). Ang II initiates intracellular oxidative stress through the protein kinase C pathway, stimulates the NADH/NADPH oxidase system, and produces large amounts of reactive oxygen species resulting in kidney tissue damage ([@b9-etm-08-01-0105]).

The mouse model of MI is useful model for studying the intrarenal abnormalities in congestive HF ([@b10-etm-08-01-0105]). An *in vitro* and *in vivo* study has shown that olmesartan medoxomil (OLM) blocks Ang II-induced physiological activity ([@b11-etm-08-01-0105]). Thus, the present study used a left anterior descending artery (LAD) ligation MI model and olmesartan intervention to observe activation of the RAS of the kidney and the protective effect of olmesartan against renal injury.

Materials and methods
=====================

Animal preparation
------------------

Ten-week-old male C57/BL/6 mice were used in the experiments. The mice were housed under climate-controlled conditions with a 12-h light/dark cycle and were provided with standard food and water *ad libitum*. All experimental procedures were performed under the guidelines for the care and use of animals as established by the China Medical University (Shenyang, China). The mice were divided into three groups: The sham surgery (SHAM) group, MI group and OLM treatment group. The surgical protocol was performed similar to methods described previously ([@b12-etm-08-01-0105]), Briefly, the mice were anesthetized by 50 mg/kg phenobarbital sodium, then the mice were orally intubated with polyethylene tubing and connected to a rodent ventilator (type 845; Harvard Apparatus Ltd., Kent, UK). Positive-pressure artificial respiration was started immediately with room air, using a volume of 1.5 ml/100 g bodyweight at a rate of 90 strokes/min to maintain the normal PCO~2~ (40 mmHg), PO~2~ (100 mmHg) and pH (7.20) parameters. The chest was opened by a left thoracotomy, followed by sectioning of the fourth and fifth ribs. The LAD was visualized and ligated with 7-0 silk suture. The chest wall was closed and the mice were allowed to recover in a temperature-controlled area. The mice were included in the MI group if there was a transmural left ventricular (LV) scar at autopsy obliterating ≥25% LV muscle. The mice in the OLM treatment group were fed a daily dose of 10 mg/kg OLM for eight weeks. Sham surgery group mice underwent the same surgery minus the coronary artery ligation.

Determination of heart rate (HR), systolic blood pressure (SBP) and cardiac function
------------------------------------------------------------------------------------

One day prior to sacrifice of the animals, an intelligent non-invasive blood pressure monitor (Kent Scientific Corporation, Torrington, CT, USA) was used to measure the SBP and HR in the awake state. Transthoracic echocardiography was performed prior to and eight weeks after the surgery using a HP 5500 imaging system (Hewlett-Packard Co., Palo Alto, CA, USA) equipped with a 15 MHz probe. The M-mode cursor was positioned perpendicular to the anterior wall in order to measure the interventricular septum, and the LV end-diastolic and end-systolic diameters (LVDd and LVDs, respectively) at the level of the papillary muscles below the mitral valve tip, and the LV ejection fraction (EF) and fractional shortening (FS) were calculated.

Determination of blood urea nitrogen (BUN) levels, serum creatinine (SCr) and urinary protein and albumin concentrations
------------------------------------------------------------------------------------------------------------------------

Following anesthesia, decapitation of the animals was used, trunk blood was collected in chilled tubes and processed for measurements of the plasma BUN levels and SCr. The urinary protein and albumin concentrations were measured using an ELISA kit (Exocell Inc., Philadelphia, PA, USA) from a one-day timed urine collection at eight weeks after the surgery.

Determination of plasma and kidney Ang II levels
------------------------------------------------

Following decapitation, trunk blood was collected from the mice in chilled tubes and the plasma was separated and stored. Simultaneously, 50 mg kidney specimens were homogenized in an ice bath and centrifuged to obtain supernatants. The Ang II levels in the plasma and renal tissue homogenate were detected with an radioimmunoassay kit according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Determination of the renal pathological changes by periodic acid-Schiff (PAS) staining
--------------------------------------------------------------------------------------

The animals were sacrificed by decapitation, followed by immediate organ collection for histological analysis. Fresh kidney sections were fixed in 10% buffered formalin and embedded in paraffin, and 4-μm sections were stained using the PAS method. A pathologist blind to the group assignments analyzed the samples and determined the levels of injury.

Determination of renin, angiotensin II type 1 receptor (AT1R) and angiotensinogen (AGT) expression levels in the kidney tissues by quantitative reverse transcription-polymerase chain reaction (PCR)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The mRNA expression levels of glyceralde-hyde-3-phosphate dehydrogenase (GAPDH), renin, AT1R and AGT were analyzed by quantitative PCR using a Light Cycler Fast Start DNA Master SYBR Green I kit (Applied Biosystems, Foster City, CA, USA) in ABI PRISM 7900T real-time PCR system (Applied Biosystems). The primer sequences are shown in [Table I](#tI-etm-08-01-0105){ref-type="table"}. For the PCR, the conditions were as follows: 30 sec at 94°C; 40 cycles at 94°C for 5 sec, 55°C for 5 sec, and 72°C for 15 sec. All data are expressed as the relative differences following normalization to the GAPDH expression levels.

Statistical analysis
--------------------

Data are expressed as mean ± standard error of the mean of the number of animals. P\<0.05 was considered to indicate a statistically significant difference. Multiple comparisons between the experimental groups were performed by one-way analysis of variance with Tukey's post hoc test.

Results
=======

General state and cardiac function changes in each group
--------------------------------------------------------

Eight weeks after the surgery, all animals in the SHAM group were alive and generally in good condition; in MI group, three mice had died due to severe HF and the remaining mice exhibited varying degrees of shortness of breath, wheezing, and eating and activity reduction; and the mice in the OLM group also showed slightly reduced eating and activity. The mice in the MI and OLM groups exhibited anatomical visible LV chamber and liver enlargement, lung congestion, pleural effusion and ascites. The transthoracic echocardiography results showed that the cardiac infarction lead to LV enlargement and systolic dysfunction when compared with the results of the sham surgery mice (P\<0.05). When compared with those of the MI mice, the mice in the OLM group had less LV enlargement (measured as the LVDd and LVDs) and less LV systolic dysfunction (evaluated using the EF and FS). The MI group also exhibited increased SBP compared with that of the SHAM group, while in the OLM group the SBP decreased compared with that in the MI group. These results are shown in [Table II](#tII-etm-08-01-0105){ref-type="table"}.

Renal injury and renal insufficiency in each group
--------------------------------------------------

In this study, the serum BUN levels, SCr, and urinary protein and albumin concentrations were examined and the results are summarized in [Table III](#tIII-etm-08-01-0105){ref-type="table"}. Cardiac infarction lead to slightly increased serum BUN levels, SCr, and urinary protein and albumin concentrations compared with those of the SHAM group (P\>0.05), and these increases were slightly attenuated in the OLM group (P\>0.05), but no statistical significance was identified.

Plasma and kidney Ang II levels in each group
---------------------------------------------

MI induced increased Ang II levels in the plasma and kidney tissues compared with those in the SHAM group (P\<0.05). However, compared with those of the MI group, the renal Ang II levels were significantly reduced, while the plasma levels were significantly increased in the OLM group (P\<0.05). The results are shown in [Table III](#tIII-etm-08-01-0105){ref-type="table"}.

Renal pathological changes shown by PAS staining
------------------------------------------------

In the SHAM group, the PAS staining indicated normal glomerular and tubular structures, renal tubular epithelial cells arranged in neat rows and no inflammatory cell infiltration in the stroma. By contrast, in the MI group, glomerular mesangial and tubular lumen expansion and irregular thickening of the basement membrane were observed, and the renal interstitial PAS positive staining was markedly increased compared with that in the SHAM group. These changes were clearly reduced in the OLM group. The results are shown in [Fig. 1](#f1-etm-08-01-0105){ref-type="fig"}.

Intrarenal RAS activation during MI
-----------------------------------

The quantitative PCR results showed that the expression levels of renin, AT1R and AGT were increased in the MI group compared with those in the SHAM group (P\<0.05). However, compared with those of the MI group, the levels were significantly reduced in the OLM group (P\<0.05). The results are shown in [Table IV](#tIV-etm-08-01-0105){ref-type="table"}.

Discussion
==========

Reduced cardiac mass following MI commonly leads to congestive HF in humans and experimental animal models ([@b12-etm-08-01-0105]). In patients with congestive HF, renal perfusion and function are often compromised, which is known as CRS ([@b13-etm-08-01-0105],[@b14-etm-08-01-0105]). Cardiac and renal dysfunctions often occur simultaneously as they share causes and pathogenetic mechanisms. There is a close association between renal and cardiac function in acute and chronic diseases. Cardiovascular disease causes \>50% of the mortalities of patients with renal failure, while poor renal function increases mortality in patients with HF ([@b15-etm-08-01-0105]). Traditionally, renal impairment has been attributed to renal hypoperfusion due to reduced cardiac output and systemic pressure. The hypovolemia leads to sympathetic activity, increased renin-angiotensin-aldosterone pathway activity and arginine-vasopressin release. In addition, as well as ischemia, inflammation and oxidative stress are considered the main determinants of cardiac and renal dysfunction ([@b16-etm-08-01-0105]).

During HF, renal perfusion reduction and RAS activation lead to progressive decline of renal function ([@b17-etm-08-01-0105]). An increasing number of studies have demonstrated that local RAS activation and the production of Ang II mediate numerous important roles, including cell growth, the long-term effects of cardiac and vascular hypertrophy, ventricular and vascular remodeling and even renal fibrosis ([@b18-etm-08-01-0105],[@b19-etm-08-01-0105]). Existing studies have verified that the effects of Ang II associated with excessive activation of the kidney RAS include the generation of oxygen free radicals, the activation of NF-κB in fibroblast proliferation, inflammation and exaggerated extracellular matrix deposition ([@b20-etm-08-01-0105],[@b21-etm-08-01-0105],[@b22-etm-08-01-0105]). Excessive production of Ang II also affects glomerular mesangial cells and podocytes, leading to glomerulosclerosis and renal dysfunction ([@b23-etm-08-01-0105]).

The model of coronary ligation in mice was selected as a previous study has documented the typical hemodynamic changes of MI in this model ([@b24-etm-08-01-0105]). In the present study, the LAD of mice was occluded for eight weeks, and the mice exhibited significant LV enlargement and systolic dysfunction of the heart, accompanied by renal dysfunction which presented as slightly increased plasma BUN levels, SCr, and urinary protein and albumin concentrations with no statistical significance. The PAS staining results identified glomerulosclerosis accompanied by intrarenal RAS activation, which manifested as increased levels of Ang II in the plasma and kidney, and increased levels of renal renin, AT1R and AGT expression, which was consistent with the results of previous study ([@b25-etm-08-01-0105]).

There are four subtypes of Ang II receptor, but the physiological effect is usually mediated by the AT1R. Studies have shown that the AT1R is widely distributed in various cells of kidney tissue. The AT1R is usually combined with Ang II and results in renal vasoconstriction, reduced renal blood flow and increased glomerular pressure and mesangial extracellular matrix production, and simultaneously stimulates the production of certain growth factors ([@b26-etm-08-01-0105]). Angiotensin II type 2 receptors (AT2Rs) are mainly distributed in the glomerular afferent arterioles and mesangial cells, which usually dilate afferent arterioles, and inhibit the growth of mesangial cells and stimulate apoptosis. AT2Rs in the kidney stimulate the generation of NO, so these two types of receptor have opposite physiological roles ([@b27-etm-08-01-0105]). OLM is a prodrug, which is absorbed via the gastrointestinal tract and hydrolyzed to form olmesartan. Olmesartan is a selective AT1R antagonist, which antagonizes the effects of Ang II by selectively blocking the binding site at which Ang II and AT1R combine. The results of the present study showed that OLM combined with AT1R substantially suppressed excessive activation of intrarenal RAS, thereby blocking Ang II damage to the kidneys. The study also demonstrated that OLM significantly increased the plasma Ang II levels, which may be combined with AT2R in the circulation and play a protective role.

In conclusion, MI activates the intrarenal RAS and leads to glomerulosclerosis, and OLM protects the kidneys by inhibiting the effects of Ang II.
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###### 

Oligonucleotide primer sequences.

  mRNA    5′ primer                 3′ primer
  ------- ------------------------- -----------------------
  Renin   GAGGCCTTCCTTGACCAATC      TGTGAATCCCACAAGCAAGG
  AT1R    GGAAACAGCTTGGTGGTGATC     CTGAGACACGTGAGCAGGAAC
  AGT     CACCCCTGCTACAGTCCATTG     GTCTGTACTGACCCCCTCCAG
  GAPDH   ATCA TCA GCAA TGCCTCCTG   CCCTCCGACGCCTGCTT

AT1R, angiotensin II type 1 receptor; AGT, angiotensinogen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

###### 

HR, SBP and echocardiography parameters of the mice (mean ± SEM; n=l0 per group).

  Group   HR (beats/min)   SBP (mmHg)                                                IVS (mm)    LVDd (mm)                                                 LVDs (mm)                                                 FS (%)                                                     EF (%)
  ------- ---------------- --------------------------------------------------------- ----------- --------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  SHAM    602.5±11.3       100.3±1.7                                                 0.95±0.02   3.29±0.42                                                 1.68±0.31                                                 42.31±5.09                                                 88.91±6.42
  MI      598.7±12.7       119.1±2.3[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   0.92±0.01   4.23±0.55[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   3.59±0.52[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   19.65±3.42[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   59.16±4.73[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}
  OLM     603.2±13.5       101.9±2.2[b](#tfn3-etm-08-01-0105){ref-type="table-fn"}   0.91±0.01   4.01±0.48[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   2.89±0.58[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   29.69±3.41[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}   66.75±5.01[a](#tfn2-etm-08-01-0105){ref-type="table-fn"}

P\<0.05 vs. SHAM group;

P\<0.05 vs. MI group.

HR, heart rate; SBP, systolic blood pressure; IVS, interventricular septum; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; FS, fractional shortening; EF, ejection fraction; SHAM, sham surgery; MI, myocardial infarction; OLM, olmesartan medoxomil.

###### 

Serum BUN levels, SCr, urinary protein and albumin excretion concentration, and plasma and kidney Ang II levels (mean ± SEM; n=l0 per group).

  Group   BUN (mmol/l)   SCr (μmol/l)   Urinary protein (mg/24 h)   Urinary albumin (μg/24 h)   Plasma Ang II (fmol/ml)                                    Kidney Ang II (fmol/g)
  ------- -------------- -------------- --------------------------- --------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  SHAM    18.4±4.9       49.6±6.8       25.5±0.7                    17.7±0.9                    64.3±20.1                                                  27.4±11.9
  MI      20.9±4.4       54.0±8.7       31.4±0.9                    20.3±5.4                    98.2±19.2[a](#tfn5-etm-08-01-0105){ref-type="table-fn"}    171.3±19.1[a](#tfn5-etm-08-01-0105){ref-type="table-fn"}
  OLM     19.7±8.2       50.6±9.3       28.3±0.6                    18.6±3.7                    218.6±36.6[b](#tfn6-etm-08-01-0105){ref-type="table-fn"}   98.7±11.5[b](#tfn6-etm-08-01-0105){ref-type="table-fn"}

P\<0.05 vs. SHAM group;

P\<0.05 vs. MI group.

BUN, blood urea nitrogen; SCr, Serum creatinine; Ang II, angiotensin II; SHAM, sham surgery; MI, myocardial infarction; OLM, olmesartan medoxomil.

###### 

Expression levels of renin, AT1R and AGT in the kidney tissue, detected by quantitative PCR (mean ± SEM; n=l0 per group).

  Group   Renin                                                     AT1R                                                      AGT
  ------- --------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------
  SHAM    0.20±0.02                                                 1.55±0.07                                                 1.00±0.10
  MI      1.31±0.07[a](#tfn8-etm-08-01-0105){ref-type="table-fn"}   2.21±0.10[a](#tfn8-etm-08-01-0105){ref-type="table-fn"}   1.74±0.07[a](#tfn8-etm-08-01-0105){ref-type="table-fn"}
  OLM     0.56±0.07[b](#tfn9-etm-08-01-0105){ref-type="table-fn"}   1.84±0.07[b](#tfn9-etm-08-01-0105){ref-type="table-fn"}   1.36±0.09[b](#tfn9-etm-08-01-0105){ref-type="table-fn"}

P\<0.05 vs SHAM group;

P\<0.05 vs MI group.

AT1R, angiotensin II type 1 receptor; AGT, angiotensinogen; PCR, polymerase chain reaction; SHAM, sham surgery; MI, myocardial infarction; OLM, olmesartan medoxomil.
